Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-419-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.52 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions
What is Syndax Pharmaceuticals' stock symbol?
Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How were Syndax Pharmaceuticals' earnings last quarter?
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.70) EPS for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.02. The business had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative net margin of 4,875.48% and a negative return on equity of 107.73%. View Syndax Pharmaceuticals' Earnings History.
When is Syndax Pharmaceuticals' next earnings date?
What price target have analysts set for SNDX?
7 Wall Street analysts have issued 1-year target prices for Syndax Pharmaceuticals' stock. Their forecasts range from $5.00 to $26.00. On average, they anticipate Syndax Pharmaceuticals' share price to reach $15.6667 in the next twelve months. This suggests a possible upside of 223.0% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals.
What is the consensus analysts' recommendation for Syndax Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals.
Has Syndax Pharmaceuticals been receiving favorable news coverage?
Press coverage about SNDX stock has trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Syndax Pharmaceuticals' key competitors?
Some companies that are related to Syndax Pharmaceuticals include Corbus Pharmaceuticals (CRBP), Assembly Biosciences (ASMB), Five Prime Therapeutics (FPRX), Corium International (CORI), Dynavax Technologies (DVAX), Akorn (AKRX), Axsome Therapeutics (AXSM), AMAG Pharmaceuticals (AMAG), Rigel Pharmaceuticals (RIGL), Catalyst Pharmaceuticals (CPRX), Theratechnologies (THERF), Innate Pharma (IPHYF), Achillion Pharmaceuticals (ACHN), OvaScience (OVAS) and MannKind (MNKD).
What other stocks do shareholders of Syndax Pharmaceuticals own?
Who are Syndax Pharmaceuticals' key executives?
Syndax Pharmaceuticals' management team includes the folowing people:
- Dr. Briggs W. Morrison, CEO & Director (Age 59)
- Mr. Michael A. Metzger, Pres & COO (Age 48)
- Mr. Richard P. Shea, CFO & Treasurer (Age 67)
- Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 68)
- Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 50)
When did Syndax Pharmaceuticals IPO?
(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Who are Syndax Pharmaceuticals' major shareholders?
Syndax Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.34%), 683 Capital Management LLC (5.41%), Dimensional Fund Advisors LP (3.26%), Dimensional Fund Advisors LP (3.26%), Sofinnova Investments Inc. (1.41%) and Bank of America Corp DE (0.92%). Company insiders that own Syndax Pharmaceuticals stock include Michael L Meyers and Peter Ordentlich. View Institutional Ownership Trends for Syndax Pharmaceuticals.
Which major investors are selling Syndax Pharmaceuticals stock?
SNDX stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, BlackRock Inc., Two Sigma Investments LP, Barclays PLC, United Services Automobile Association and HighPoint Advisor Group LLC. View Insider Buying and Selling for Syndax Pharmaceuticals.
Which major investors are buying Syndax Pharmaceuticals stock?
SNDX stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Sofinnova Investments Inc., Bank of America Corp DE, MCF Advisors LLC, Caption Management LLC, Telemetry Investments L.L.C., Raymond James & Associates and Bank of New York Mellon Corp. View Insider Buying and Selling for Syndax Pharmaceuticals.
How do I buy shares of Syndax Pharmaceuticals?
Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syndax Pharmaceuticals' stock price today?
One share of SNDX stock can currently be purchased for approximately $4.85.
How big of a company is Syndax Pharmaceuticals?
Syndax Pharmaceuticals has a market capitalization of $121.25 million and generates $1.52 million in revenue each year. The company earns $-73,960,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.
What is Syndax Pharmaceuticals' official website?
How can I contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]
MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)
MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
